Table 1 (abstract P279). Characteristic features and antinuclear antibody patterns of 41 patients
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
|  | Anti-NXP2 (n=13) | Anti-TIF-1γ (n=10) | Anti-Mi-2 (n=7) | Anti-MDA5 (n=5) | Anti-PmScl75 (n=5) | Anti-PmScl100 (n=6) | Anti-Ku (n=4) | Others (n=6) |
|---|---|---|---|---|---|---|---|---|
Age, years, median (min-max) | 7.5 (3.5-11.7) | 8.5 (1.4-12.8) | 9.7 (2.4-16.9) | 13.1 (6.4-16.8) | 6.5 (2.5-12.1) | 9.4 (6.8-14.5) | 11.3 (2.5-13.9) | 10.2 (4.3-14.7) |
Gender, female, n (%) | 8 (61.5) | 6 (60) | 4 (57.1) | 3 (60) | 4 (80) | 4 (66.6) | 4 (100) | 4 (66.6) |
Elevated CK levels, n (%) | 11 (84.6) | 6 (60) | 4 (57.1) | 2 (40) | 1 (20) | 2 (33.3) | 3 (75) | 2 (33.3) |
Muscle weakness, n (%) | 11 (84.6) | 8 (80) | 7 (100) | 2 (40) | 2 (40) | 2 (33.3) | 3 (75) | 3 (50) |
Calcinosis, n (%) | 5 (35.7) | 5 (50) | 1 (14.3) | 2 (40) | 1 (20) | 0 | 1 (25) | 0 |
GIS involvement, n (%) | 2 (14.3) | 0 | 0 | 1 (20) | 0 | 1 (16.6) | 0 | 0 |
Pulmonary involvement, n (%) | 2 (14.3) | 0 | 0 | 2 (40) | 0 | 1 (16.6) | 0 | 0 |
Cardiac involvement, n (%) | 0 | 1 (10) | 0 | 0 | 0 | 0 | 0 | 0 |
ANA patterns, n (%) | ||||||||
 AC4 | 4 (80) | 5 (83.3) | 5 (100) | 4 (80) | 4 (100) | 6 (100) | 3 (100) | 1 (16.6) |
 AC5 | 2 (40) | 4 (66.6) | 5 (100) | 4 (80) | 4 (100) | 4 (66.6) | 3 (100) | 1 (16.6) |
 AC1 | 1 (20) | 0 | 0 | 1 (20) | 0 | 1 (16.6) | 0 | 0 |
 Others | 2 (40) | 1 (16.6) | 1 (20) | 1 (20) | 0 | 0 | 0 | 0 |